We believe the best way to address this challenge is to treat a patient with more than one TCR-T simultaneously (what we refer to as “multiplex therapy”). To do this, we are developing an ImmunoBank, a portfolio of TCR-T product candidates designed to elicit an anti-tumor response by simultaneously targeting multiple cancer-specific antigens in tumor cells.

Our vision is to build the ImmunoBank with TCRs that recognize diverse targets and are associated with multiple HLA types to provide a broad array of therapeutic options for patients with various types of solid tumors.

For patients with a solid tumor, we first determine which targets are expressed and which HLA genes are still intact within their tumor cells. We then select up to three TCRs from the ImmunoBank that match their HLA type and address the most highly expressed targets in their tumor. Using these TCRs, we genetically reprogram the patient’s T cells to recognize their cancer cells and then infuse the engineered T cells back into the patient as multiplex TCR-T therapy. For more detailed information about our ongoing clinical study please visit: NCT05973487